National Center for Advancing Translational Sciences funding in FY2024

How CFDA 93.350 meets FY2024 in the award file

This page is a join: National Center For Advancing Translational Sciences and fiscal year 2024. $4,823,252,647.16 is the USAspending.gov obligation sum on the yearlyTrend row that carries both tags. It is not every federal dollar in FY2024, not an outlay register, and not a drug-approval count, a trial-site roster, or a biotech-valuation table. The FY cell is 92.8% of the program-wide $5,195,080,963.66 book in this extract. A different fiscal year for CFDA 93.350 is a separate overlay. Campaign-finance tables are a different dataset; FEC donations do not fund these USAspending obligations.

CFDA 93.350 is the listing without the year filter. FY2024 federal spending is the year without this CFDA filter. All programs lists other catalog hubs. All spending ties indexes other pairs. Only this tie applies both filters. 554 is the year-cell award-record count; the program parent lists 768 awards across the extract. Those counts are different tables.

National Center for Advancing Translational Sciences as the program side of the FY2024 join

The official title is NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES. SpendingVault does not grade National Center for Advancing Translational Sciences. $4,823,252,647.16 is an obligation sum, not a verdict. Confusing this join with other biomedical-research catalog lines that are not CFDA 93.350 would be a different table. Packet facts on the program side are the name National Center For Advancing Translational Sciences, number 93.350, program-wide obligations $5,195,080,963.66, and 768 awards on the parent. This packet lists no award recipients and no contractor names.

National Center For Advancing Translational Sciences is the catalog title on CFDA 93.350. The name identifies the listing; this packet still publishes no awarding-agency code and no recipient names. FY2024 is the yearlyTrend year. Do not treat the cell as approvals already issued or as a count of translational hubs. Institution names are unpublished.

What fiscal year 2024 contributes on CFDA 93.350

FY2024 is a USAspending yearlyTrend bucket, not a calendar-year close and not a claim that every obligated dollar was delivered inside calendar 2024. Awards can list FY2024 while performance stretches across adjacent years. FY figures can be incomplete for a current year; this snapshot reports $4,823,252,647.16 as given. Other fiscal years for CFDA 93.350 belong on those ties. Do not treat $5,195,080,963.66 as if it were the FY2024 headline.

554 awards on the FY2024 cell, not a unit census

The extract lists 554 awards on National Center for Advancing Translational Sciences in FY2024. That is an award-record count, not 554 unique hubs, compounds, or investigators. Dividing $4,823,252,647.16 by 554 yields about $8,706,232.22 as a quotient of two packet facts, not a typical invoice and not a median. Unique recipients are unpublished. Modifications can add rows without naming a new organization. Do not mix $4,823,252,647.16 with the parent’s 768 awards.

Obligations on National Center for Advancing Translational Sciences are not cash already cleared in FY2024

An obligation is a legal commitment. An outlay is a payment. $4,823,252,647.16 is the former. Citing it as cash already cleared in FY2024 over-reads the field. The join cannot say that fiscal year 2024 specialized in National Center for Advancing Translational Sciences because of federal demand. Keep $4,823,252,647.16 labeled as National Center For Advancing Translational Sciences obligations in FY2024. It is not a named-compound list, a hub-and-spoke census, or a patent inventory.

Open /programs/93.350/ for the program rollup, /fiscal-years/2024/ for the fiscal-year rollup, /programs/ for other CFDA hubs, and /ties/ for other pairs. None of those links convert this cell into a drug-approval count, a trial-site roster, or a biotech-valuation table, into outlays this packet omits, or into a contractor list. Cite both sides: National Center For Advancing Translational Sciences and FY2024, CFDA 93.350, $4,823,252,647.16, 554 awards, USAspending.gov, obligations only. Keep National Center For Advancing Translational Sciences and FY2024 on the same line as $4,823,252,647.16.

Questions

How much National Center for Advancing Translational Sciences spending is in FY2024?

USAspending.gov records $4,823,252,647.16 in National Center For Advancing Translational Sciences obligations for FY2024 (CFDA 93.350). That is a program × year join, not an outlay and not the government-wide FY2024 total. Original filings remain on USAspending.gov.

Do 554 awards mean 554 translational hubs in FY2024?

No. 554 is the year-cell award-record count, not 554 unique hubs, compounds, or investigators. A mean of about $8,706,232.22 is arithmetic on packet facts, not a typical payment. Unique recipients are unpublished. Original filings remain on USAspending.gov.

Is $4,823,252,647.16 cash already paid for National Center for Advancing Translational Sciences in FY2024?

No. $4,823,252,647.16 is an obligation aggregate for National Center For Advancing Translational Sciences in FY2024. Outlays, remaining balances, and cash already paid are unpublished on this packet. Keep the obligation label. USAspending.gov remains the source.

Which pages parent National Center for Advancing Translational Sciences FY2024?

CFDA 93.350 is the program parent. FY2024 federal spending is the year parent. All programs lists other CFDA hubs. All spending ties lists other pairs. Prefer those tables after later ingests; this page quotes National Center For Advancing Translational Sciences × FY2024 at $4,823,252,647.16.